On Wednesday, President Donald Trump announced a $100 billion new opioid program aimed at reducing opioid deaths.
But the news didn’t come as a complete surprise.
As Vox’s Dylan Matthews wrote in March, the opioid crisis has been building for years.
The opioid crisis is part of a broader opioid crisis in the United States, where more people die from opioid-related illnesses than any other developed country, according to a study published last month by Johns Hopkins University’s Bloomberg School of Public Health.
It’s a crisis that’s exacerbated by the opioid epidemic, and it’s exacerbated in part by the rise of alternative treatments, like methadone and buprenorphine.
The new opioids program was designed to address that crisis by funding research and education on opioid addiction, and to help states craft opioid laws that will help prevent the next crisis from occurring.
But Trump’s announcement has drawn scrutiny for its ties to the pharmaceutical industry, and the opioid industry has been critical of the president’s opioid plan.
In an op-ed published in The Hill on Tuesday, pharmaceutical company Pfizer and opioid manufacturer Purdue Pharma slammed the opioid plan as “an expensive, misguided, and unworkable program” that would lead to increased addiction.
“In many cases, the government can help patients who are already struggling by reducing costs, including by expanding access to affordable opioid medications,” the companies wrote.
“But the administration is trying to do just that by allowing states to decide what to do with opioids for their residents.”
In an interview with Vox on Wednesday, Dr. Paul Volcker, a professor of medicine and pharmacology at the University of Washington, said that while the opioid companies support Trump’s opioid push, the drug makers are also “very concerned” about the president and the program’s effects.
The drug makers see the opioid overdose crisis as a public health threat, and are worried that it could result in increased drug addiction.
The industry sees it as a direct threat to their business, Volcker said.
They’re very concerned about what happens to the American consumer when there’s a pandemic, and there’s this new epidemic that they’re seeing in the form of opioids.
“They see the [Trump] administration as a threat to the entire pharmaceutical industry,” Volcker told Vox.
The pharmaceutical industry’s concerns are echoed by many other groups.
The National Institutes of Health, which oversees the National Institutes for Health, has warned of a potential pandemic in which the opioid use and overdose epidemic will continue to increase.
The Trump administration has pledged to spend $1.2 billion on a new opioid crisis initiative that it has yet to detail, and that includes funding for a task force to study how to address the problem.
But many doctors are worried about how the program would affect their patients.
“I think that the government would be a better choice if it had really listened to the doctors,” said Dr. David Hochberg, director of the division of clinical pharmacology and neuroscience at the Johns Hopkins Bloomberg School and a former president of the American College of Physicians.
“The pharmaceutical industry has a very, very strong relationship with the president.
The administration could have spent a lot of time trying to find a way for the administration to work with the industry, but they’ve made it very clear that they don’t want to.”
The opioid epidemic is a problem that affects every region of the country, but the pharmaceuticals that make up the majority of those drugmakers are the ones with the most influence over how the government regulates opioid prescribing.
The Centers for Disease Control and Prevention has identified opioids as a leading cause of overdose deaths, and opioid addiction has been identified as a risk factor for many other health problems.
The problem is particularly acute in states that have tried to limit opioid prescriptions, including Ohio, New York, and South Carolina.
The president’s proposal to address opioid addiction was designed as a way to get states to limit prescriptions of opioid painkillers to the same levels as prescription painkillers, but it also aimed to help reduce addiction rates and increase access to opioid medication.
The White House says the program will allow states to craft better laws and policies, which could reduce the amount of opioid prescriptions being given.
The Obama administration spent years trying to address addiction to prescription opioids with prescription drug monitoring programs, including a series of federal lawsuits that helped establish the system, but these programs were also plagued by political pressure from pharmaceutical companies.
The companies that make opioid pain pills are also lobbying to cut off funding to programs that help people with opioid addiction.
And the pharmaceutical companies, as well as a coalition of doctors, have fought efforts to regulate opioid prescribing and treatment.
And in many cases the pharmaceutical industries are also skeptical of the administration’s commitment to opioids, because the opioid addiction crisis has a lot to do more with the rise in alternative treatments for opioid addiction than with the opioid government.
“There are a lot more than one group at the root of this,” said William Schaffner, the chief executive officer of